Supemtek (Quadrivalent Influenza Vaccine, recombinant prepared in cell-culture), is manufactured using recombinant technology.1
Watch the video below to find out more about how Supemtek is manufactured.
Recombinant technology eliminates the possibility of adaptation or mutation by replicating only the haemagglutinin (HA) antigen direct from a genetic sequence. The resulting antigens are an exact genetic match to the target strain.2,3
In the production of Supemtek, the HA antigen DNA for each World Health Organization (WHO)-recommended influenza strain is combined with host cell DNA.1,3 Because only the DNA for each influenza antigen is used, there is no live virus replication during the recombinant process.3
Supemtek contains 3x more HA antigen (45 mcg versus 15 mcg) per strain, compared with cell- and egg-based standard-dose quadrivalent influenza vaccines.2
HOW DOES RECOMBINANT TECHNOLOGY WORK?1,3,4
RECOMBINANT TECHNOLOGY GENERATES HA ANTIGENS THAT ARE AN EXACT GENETIC MATCH TO THE TARGET STRAINS2,3
This eliminates the possibility of adaptation or mutation.2,3
CVV, Candidate Vaccine Virus; HA, haemagglutinin; WHO, World Health Organization.
Date of preparation: November 2021 | MAT-GB-2003350(v3.0)
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on 0800 0902 314. Alternatively send via email to